A novel synthetic TLR-4 agonist adjuvant increases the protective response to a clinical-stage West Nile virus vaccine antigen in multiple formulations

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Van Hoeven, Neal ^a   Joshi, Sharvari Waghmare ^a   Nana, Ghislain Ismael ^a   Bosco Lauth, Angela ^b   Fox, Christopher ^a   Bowen, Richard A ^b   Clements, David E ^c   Martyak, Timothy ^c   Parks, D Elliot ^c   Baldwin, Susan ^a   Reed, Steven G ^a   Coler, Rhea N ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c HAWAII BIOTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; E PROTEIN VACCINE; IMMUNOGLOBULIN G ANTIBODY; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; WEST NILE VACCINE; GLYCOPROTEIN E, FLAVIVIRUS; IMMUNOLOGICAL ADJUVANT; TLR4 PROTEIN, MOUSE; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BLOOD ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG FORMULATION; DRUG POTENTIATION; EMULSION; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; MOUSE; NONHUMAN; T LYMPHOCYTE; VIRAL PLAQUE ASSAY; VIRUS LOAD; WEST NILE FEVER; AGONISTS; ANIMAL; CELLULAR IMMUNITY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; IMMUNOLOGY; TH1 CELL; WEST NILE VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNITY, CELLULAR; MICE; TH1 CELLS; TOLL-LIKE RECEPTOR 4; VIRAL ENVELOPE PROTEINS; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

EID: 84960540616     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149610     Document Type: Article

References (91)

1. Pepperell C, Rau N, Krajden S, Kern R, Humar A, Mederski B, et al. West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario. CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne. 2003; 168(11):1399-405. PMID: 12771068; Pub Med Central PMCID: PMC155955.
2. Deardorff E, Estrada-Franco J, Brault AC, Navarro-Lopez R, Campomanes-Cortes A, Paz-Ramirez P, et al. Introductions of West Nile virus strains to Mexico. Emerging infectious diseases. 2006; 12 (2):314-8. doi: 10.3201/eid1202.050871 PMID: 16494762; Pub Med Central PMCID: PMC3373085.
3. Morales MA, Barrandeguy M, Fabbri C, Garcia JB, Vissani A, Trono K, et al. West Nile virus isolation from equines in Argentina, 2006. Emerging infectious diseases. 2006; 12(10):1559-61. doi: 10.3201/eid1210.060852 PMID: 17176571; Pub Med Central PMCID: PMC3290965.
4. Lindsey NP, Staples JE, Lehman JA, Fischer M, Centers for Disease C, Prevention. Surveillance for human West Nile virus disease-United States, 1999-2008. Morbidity and mortality weekly report Surveillance summaries. 2010; 59(2):1-17. PMID: 20360671.
5. Petersen LR, Carson PJ, Biggerstaff BJ, Custer B, Borchardt SM, Busch MP. Estimated cumulative incidence of West Nile virus infection in US adults, 1999-2010. Epidemiology and infection. 2013; 141 (3):591-5. doi: 10.1017/S0950268812001070 PMID: 22640592.
6. CDC. West Nile virus disease cases and deaths reported to CDC by year and clinical presentation, 1999-2014: Centers for Disease Control And Prevention; 2015. Available from: http://www.cdc.gov/westnile/statsmaps/index.html.
7. Petersen LR, Brault AC, Nasci RS. West Nile virus: review of the literature. Jama. 2013; 310(3):308-15 doi: 10.1001/jama.2013.8042 PMID: 23860989.
8. Sejvar JJ. Clinical manifestations and outcomes of West Nile virus infection. Viruses. 2014; 6(2):606-23 doi: 10.3390/v6020606 PMID: 24509812; Pub Med Central PMCID: PMC3939474.
9. Barzon L, Pacenti M, Palu G. West Nile virus and kidney disease. Expert review of anti-infective therapy. 2013; 11(5):479-87. doi: 10.1586/eri.13.34 PMID: 23627854.
10. Brinton MA. Replication cycle and molecular biology of the West Nile virus. Viruses. 2014; 6(1):13-53. doi: 10.3390/v6010013 PMID: 24378320; Pub Med Central PMCID: PMC3917430.
11. Nybakken GE, Nelson CA, Chen BR, Diamond MS, Fremont DH. Crystal structure of the West Nile virus envelope glycoprotein. Journal of virology. 2006; 80(23):11467-74. doi: 10.1128/JVI.01125-06 PMID: 16987985; Pub Med Central PMCID: PMC1642602.
12. Kanai R, Kar K, Anthony K, Gould LH, Ledizet M, Fikrig E, et al. Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes. Journal of virology. 2006; 80(22):11000-8. doi: 10.1128/JVI.01735-06 PMID: 16943291; Pub Med Central PMCID: PMC1642136.
13. Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100(12):6986-91. doi: 10.1073/pnas.0832193100 PMID: 12759475; Pub Med Central PMCID: PMC165817.
14. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature. 1995; 375(6529):291-8. doi: 10.1038/375291a0 PMID: 7753193.
15. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. Structural insights into the mechanisms of antibodymediated neutralization of flavivirus infection: implications for vaccine development. Cell host & microbe. 2008; 4(3):229-38. doi: 10.1016/j.chom.2008.08.004 PMID: 18779049; Pub Med Central PMCID: PMC2678546.
16. Amanna IJ, Slifka MK. Current trends in West Nile virus vaccine development. Expert review of vaccines. 2014; 13(5):589-608. doi: 10.1586/14760584.2014.906309 PMID: 24689659.
17. Brandler S, Tangy F. Vaccines in development against West Nile virus. Viruses. 2013; 5(10):2384-409. doi: 10.3390/v5102384 PMID: 24084235; Pub Med Central PMCID: PMC3814594.
18. Pinto AK, Richner JM, Poore EA, Patil PP, Amanna IJ, Slifka MK, et al. A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice. Journal of virology. 2013; 87(4):1926-36. doi: 10.1128/JVI.02903-12 PMID: 23221549; Pub Med Central PMCID: PMC3571480.
19. Samina I, Havenga M, Koudstaal W, Khinich Y, Koldijk M, Malkinson M, et al. Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine. Vaccine. 2007; 25(49):8338-45. doi: 10.1016/j.vaccine.2007.09.055 PMID: 17977629.
20. Lim CK, Takasaki T, Kotaki A, Kurane I. Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine. Virology. 2008; 374 (1):60-70. doi: 10.1016/j.virol.2007.12.021 PMID: 18221765.
21. Orlinger KK, Holzer GW, Schwaiger J, Mayrhofer J, Schmid K, Kistner O, et al. An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system. Vaccine. 2010; 28(19):3318-24. doi: 10.1016/j.vaccine.2010.02.092 PMID: 20211218.
22. Muraki Y, Fujita T, Matsuura M, Fuke I, Manabe S, Ishikawa T, et al. The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys. Virology journal. 2015; 12(1):54. doi: 10.1186/s12985-015-0282-8 PMID: 25889682; Pub Med Central PMCID: PMC4403780.
23. Qiao M, Ashok M, Bernard KA, Palacios G, Zhou ZH, Lipkin WI, et al. Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells. The Journal of infectious diseases. 2004; 190(12):2104-8. doi: 10.1086/425933 PMID: 15551208.
24. Magnusson SE, Karlsson KH, Reimer JM, Corbach-Sohle S, Patel S, Richner JM, et al. Matrix-M adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice. Vaccine. 2014; 32(7):800-8. doi: 10.1016/j.vaccine.2013.12.030 PMID: 24380682.
25. Lieberman MM, Nerurkar VR, Luo H, Cropp B, Carrion R Jr., de la Garza M, et al. Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Clinical and vaccine immunology: CVI. 2009; 16(9):1332-7. doi: 10.1128/CVI.00119-09 PMID: 19641099; Pub Med Central PMCID: PMC2745014.
26. Lieberman MM, Clements DE, Ogata S, Wang G, Corpuz G, Wong T, et al. Preparation and immunogenic properties of a recombinant West Nile subunit vaccine. Vaccine. 2007; 25(3):414-23. doi: 10.1016/j.vaccine.2006.08.018 PMID: 16996661; Pub Med Central PMCID: PMC1839850.
27. Wang T, Anderson JF, Magnarelli LA, Wong SJ, Koski RA, Fikrig E. Immunization of mice against West Nile virus with recombinant envelope protein. Journal of immunology. 2001; 167(9):5273-7. PMID: 11673542.
28. Ledizet M, Kar K, Foellmer HG, Wang T, Bushmich SL, Anderson JF, et al. A recombinant envelope protein vaccine against West Nile virus. Vaccine. 2005; 23(30):3915-24. doi: 10.1016/j.vaccine.2005. 03.006 PMID: 15917113.
29. Demento SL, Bonafe N, Cui W, Kaech SM, Caplan MJ, Fikrig E, et al. TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. Journal of immunology. 2010; 185(5):2989-97. doi: 10.4049/jimmunol.1000768 PMID: 20660705; Pub Med Central PMCID: PMC3753007.
30. McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, Desai P, et al. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. The Journal of infectious diseases. 2007; 195(11):1607-17. doi: 10.1086/517613 PMID: 17471430.
31. Spohn G, Jennings GT, Martina BE, Keller I, Beck M, Pumpens P, et al. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virology journal. 2010; 7:146. doi: 10.1186/1743-422X-7-146 PMID: 20604940; Pub Med Central PMCID: PMC2914671.
32. Chua AJ, Vituret C, Tan ML, Gonzalez G, Boulanger P, Ng ML, et al. A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies. Virology journal. 2013; 10:129. doi: 10.1186/1743-422X-10-129 PMID: 23617954; Pub Med Central PMCID: PMC3668303.
33. Merino-Ramos T, Blazquez AB, Escribano-Romero E, Canas-Arranz R, Sobrino F, Saiz JC, et al. Protection of a single dose west nile virus recombinant subviral particle vaccine against lineage 1 or 2 strains and analysis of the cross-reactivity with Usutu virus. PloS one. 2014; 9(9):e108056. doi: 10.1371/journal.pone.0108056 PMID: 25229345; Pub Med Central PMCID: PMC4168257.
34. Davis BS, Chang GJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. Journal of virology. 2001; 75(9):4040-7. doi: 10.1128/JVI.75.9.4040-4047.2001 PMID: 11287553; Pub Med Central PMCID: PMC114149.
35. Ishikawa T, Takasaki T, Kurane I, Nukuzuma S, Kondo T, Konishi E. Co-immunization with West Nile DNA and inactivated vaccines provides synergistic increases in their immunogenicities in mice. Microbes and infection/Institut Pasteur. 2007; 9(9):1089-95. doi: 10.1016/j.micinf.2007.05.013 PMID: 17644390.
36. Anwar A, Chandrasekaran A, Ng ML, Marques E, August JT. West Nile premembrane-envelope genetic vaccine encoded as a chimera containing the transmembrane and cytoplasmic domains of a lysosome-associated membrane protein: increased cellular concentration of the transgene product, targeting to the MHC II compartment, and enhanced neutralizing antibody response. Virology. 2005; 332 (1):66-77. doi: 10.1016/j.virol.2004.11.022 PMID: 15661141.
37. Ramanathan MP, Kutzler MA, Kuo YC, Yan J, Liu H, Shah V, et al. Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII. Vaccine. 2009; 27(32):4370-80. doi: 10.1016/j.vaccine.2009.01.137 PMID: 19497647.
38. Seregin A, Nistler R, Borisevich V, Yamshchikov G, Chaporgina E, Kwok CW, et al. Immunogenicity of West Nile virus infectious DNA and its noninfectious derivatives. Virology. 2006; 356(1-2):115-25. doi: 10.1016/j.virol.2006.07.038 PMID: 16935318.
39. Chang DC, Liu WJ, Anraku I, Clark DC, Pollitt CC, Suhrbier A, et al. Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus. Nature biotechnology. 2008; 26 (5):571-7. doi: 10.1038/nbt1400 PMID: 18425125.
40. Hall RA, Nisbet DJ, Pham KB, Pyke AT, Smith GA, Khromykh AA. DNA vaccine coding for the fulllength infectious Kunjin virus RNA protects mice against the New York strain of West Nile virus. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100(18):10460-4 doi: 10.1073/pnas.1834270100 PMID: 12917491; Pub Med Central PMCID: PMC193583.
41. Schneeweiss A, Chabierski S, Salomo M, Delaroque N, Al-Robaiy S, Grunwald T, et al. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII. Vaccine. 2011; 29(37):6352-7. doi: 10.1016/j.vaccine.2011.04.116 PMID: 21596075.
42. Kim DY, Atasheva S, McAuley AJ, Plante JA, Frolova EI, Beasley DW, et al. Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic RNAs. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111(29):10708-13. doi: 10.1073/pnas.1408677111 PMID: 25002490; Pub Med Central PMCID: PMC4115546.
43. Tesh RB, Arroyo J, Travassos Da Rosa AP, Guzman H, Xiao SY, Monath TP. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerging infectious diseases. 2002; 8(12):1392-7. doi: 10.3201/eid0812.020229 PMID: 12498653; Pub Med Central PMCID: PMC2738528.
44. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010; 28(3):632-49. doi: 10.1016/j.vaccine.2009.09.098 PMID: 19808029.
45. Long MT, Gibbs EP, Mellencamp MW, Bowen RA, Seino KK, Zhang S, et al. Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model. Equine veterinary journal. 2007; 39(6):491-7. doi: 10.2746/042516407X217416 PMID: 18065305.
46. Pletnev AG, Claire MS, Elkins R, Speicher J, Murphy BR, Chanock RM. Molecularly engineered liveattenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology. 2003; 314(1):190-5. PMID: 14517072.
47. Karaca K, Bowen R, Austgen LE, Teehee M, Siger L, Grosenbaugh D, et al. Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge. Vaccine. 2005; 23(29):3808-13. doi: 10.1016/j.vaccine.2005.02.020 PMID: 15893618.
48. Siger L, Bowen RA, Karaca K, Murray MJ, Gordy PW, Loosmore SM, et al. Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses. American journal of veterinary research. 2004; 65 (11):1459-62. PMID: 15566080.
49. Iglesias MC, Frenkiel MP, Mollier K, Souque P, Despres P, Charneau P. A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus. The journal of gene medicine. 2006; 8(3):265-74. doi: 10.1002/jgm.837 PMID: 16308885.
50. Coutant F, Frenkiel MP, Despres P, Charneau P. Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PloS one. 2008; 3(12):e3973. doi: 10.1371/journal.pone. 0003973 PMID: 19096527; Pub Med Central PMCID: PMC2600612.
51. Despres P, Combredet C, Frenkiel MP, Lorin C, Brahic M, Tangy F. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. The Journal of infectious diseases. 2005; 191(2):207-14. doi: 10.1086/426824 PMID: 15609230.
52. Brandler S, Marianneau P, Loth P, Lacote S, Combredet C, Frenkiel MP, et al. Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection. The Journal of infectious diseases. 2012; 206(2):212-9. doi: 10.1093/infdis/jis328 PMID: 22551814.
53. Iyer AV, Pahar B, Boudreaux MJ, Wakamatsu N, Roy AF, Chouljenko VN, et al. Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01. Vaccine. 2009; 27 (6):893-903. doi: 10.1016/j.vaccine.2008.11.087 PMID: 19070640.
54. Schepp-Berglind J, Luo M, Wang D, Wicker JA, Raja NU, Hoel BD, et al. Complex adenovirus-mediated expression of West Nile virus C, Pre ME, and NS1 proteins induces both humoral and cellular immune responses. Clinical and vaccine immunology: CVI. 2007; 14(9):1117-26. doi: 10.1128/CVI. 00070-07 PMID: 17634508; Pub Med Central PMCID: PMC2043313.
55. Lustig S, Olshevsky U, Ben-Nathan D, Lachmi BE, Malkinson M, Kobiler D, et al. A live attenuated West Nile virus strain as a potential veterinary vaccine. Viral immunology. 2000; 13(4):401-10. PMID: 11192286.
56. Yamshchikov G, Borisevich V, Seregin A, Chaporgina E, Mishina M, Mishin V, et al. An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development. Virology. 2004; 330(1):304-12. doi: 10.1016/j.virol.2004.09.014 PMID: 15527855.
57. Whiteman MC, Li L, Wicker JA, Kinney RM, Huang C, Beasley DW, et al. Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus. Vaccine. 2010; 28(4):1075-83. doi: 10.1016/j.vaccine.2009.10.112 PMID: 19896447.
58. Yu L, Robert Putnak J, Pletnev AG, Markoff L. Attenuated West Nile viruses bearing 3′ SL and envelope gene substitution mutations. Vaccine. 2008; 26(47):5981-8. doi: 10.1016/j.vaccine.2008.08.064 PMID: 18805457.
59. Liu WJ, Wang XJ, Clark DC, Lobigs M, Hall RA, Khromykh AA. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. Journal of virology. 2006; 80(5):2396-404. doi: 10.1128/JVI.80. 5.2396-2404.2006 PMID: 16474146; Pub Med Central PMCID: PMC1395377.
60. Wicker JA, Whiteman MC, Beasley DW, Davis CT, Zhang S, Schneider BS, et al. A single amino acid substitution in the central portion of the West Nile virus NS4B protein confers a highly attenuated phenotype in mice. Virology. 2006; 349(2):245-53. doi: 10.1016/j.virol.2006.03.007 PMID: 16624366.
61. Widman DG, Ishikawa T, Giavedoni LD, Hodara VL, Garza Mde L, Montalbo JA, et al. Evaluation of Repli VAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection. The American journal of tropical medicine and hygiene. 2010; 82(6):1160-7. doi: 10.4269/ajtmh. 2010.09-0310 PMID: 20519618; Pub Med Central PMCID: PMC2877429.
62. Biedenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. The Journal of infectious diseases. 2011; 203(1):75-84. doi: 10.1093/infdis/jiq003 PMID: 21148499; Pub Med Central PMCID: PMC3086439.
63. Durbin AP, Wright PF, Cox A, Kagucia W, Elwood D, Henderson S, et al. The live attenuated chimeric vaccine rWN/DEN4Delta30 is well-tolerated and immunogenic in healthy flavivirus-naive adult volunteers. Vaccine. 2013; 31(48):5772-7. doi: 10.1016/j.vaccine.2013.07.064 PMID: 23968769; Pub Med Central PMCID: PMC3833717.
64. Dayan GH, Bevilacqua J, Coleman D, Buldo A, Risi G. Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults >/= 50 years of age. Vaccine. 2012; 30(47):6656-64. doi: 10.1016/j.vaccine.2012.08.063 PMID: 22959989.
65. Coller BA PV, Weeks-Levy C, Ogata S. United States patent application No. US20120141520 A1: Recombinant subunit West Nile virus vaccine for protection of human subjects. 2012.
66. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nature medicine. 2013; 19 (12):1597-608. doi: 10.1038/nm.3409 PMID: 24309663.
67. Vasilakos JP, Tomai MA. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants. Expert review of vaccines. 2013; 12(7):809-19. doi: 10.1586/14760584.2013.811208 PMID: 23885825.
68. Scheiermann J, Klinman DM. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine. 2014. doi: 10.1016/j.vaccine.2014.06.065 PMID: 24975812.
69. Shirota H, Klinman DM. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert review of vaccines. 2014; 13(2):299-312. doi: 10.1586/14760584.2014.863715 PMID: 24308579.
70. Mizel SB, Bates JT. Flagellin as an adjuvant: cellular mechanisms and potential. Journal of immunology. 2010; 185(10):5677-82. doi: 10.4049/jimmunol.1002156 PMID: 21048152; Pub Med Central PMCID: PMC3756556.
71. Alving CR, Peachman KK, Rao M, Reed SG. Adjuvants for human vaccines. Current opinion in immunology. 2012; 24(3):310-5. doi: 10.1016/j.coi.2012.03.008 PMID: 22521140; Pub Med Central PMCID: PMC3383374.
72. Ireton GC, Reed SG. Adjuvants containing natural and synthetic Toll-like receptor 4 ligands. Expert review of vaccines. 2013; 12(7):793-807. doi: 10.1586/14760584.2013.811204 PMID: 23885824.
73. Chu JH, Chiang CC, Ng ML. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. Journal of immunology. 2007; 178(5):2699-705. PMID: 17312111.
74. Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PloS one. 2011; 6(1):e16333. doi: 10.1371/journal.pone.0016333 PMID: 21298114; Pub Med Central PMCID: PMC3027669.
75. Monath TP, Liu J, Kanesa-Thasan N, Myers GA, Nichols R, Deary A, et al. A live, attenuated recombinant West Nile virus vaccine. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(17):6694-9. doi: 10.1073/pnas.0601932103 PMID: 16617103; Pub Med Central PMCID: PMC1436023.
76. Seligman SJ. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine. 2014; 32(44):5769-75. doi: 10.1016/j.vaccine.2014.08.051 PMID: 25192973.
77. O'Leary DR, Marfin AA, Montgomery SP, Kipp AM, Lehman JA, Biggerstaff BJ, et al. The epidemic of West Nile virus in the United States, 2002. Vector borne and zoonotic diseases. 2004; 4(1):61-70. doi: 10.1089/153036604773083004 PMID: 15018774.
78. Tsai TF, Popovici F, Cernescu C, Campbell GL, Nedelcu NI. West Nile encephalitis epidemic in southeastern Romania. Lancet. 1998; 352(9130):767-71. PMID: 9737281.
79. Chowers MY, Lang R, Nassar F, Ben-David D, Giladi M, Rubinshtein E, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerging infectious diseases. 2001; 7(4):675-8. doi: 10.3201/eid0704.010414 PMID: 11585531; Pub Med Central PMCID: PMC2631759.
80. Clegg CH, Roque R, Perrone LA, Rininger JA, Bowen R, Reed SG. GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza. PloS one. 2014; 9(2):e88979. doi: 10.1371/journal.pone.0088979 PMID: 24551202; Pub Med Central PMCID: PMC3925208.
81. Clegg CH, Roque R, Van Hoeven N, Perrone L, Baldwin SL, Rininger JA, et al. Adjuvant solution for pandemic influenza vaccine production. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(43):17585-90. doi: 10.1073/pnas.1207308109 PMID: 23045649; Pub Med Central PMCID: PMC3491477.
82. Morrey JD, Siddharthan V, Wang H. Neurological approaches for investigating West Nile virus disease and its treatment in rodents. Antiviral Res. 2013; 100(2):535-45. doi: 10.1016/j.antiviral.2013.09.010 PMID: 24055448.
83. Siirin MT, Travassos da Rosa AP, Newman P, Weeks-Levy C, Coller BA, Xiao SY, et al. Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters. The American journal of tropical medicine and hygiene. 2008; 79(6):955-62. PMID: 19052311; Pub Med Central PMCID: PMC2765405.
84. Wiley SR, Raman VS, Desbien A, Bailor HR, Bhardwaj R, Shakri AR, et al. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Science translational medicine. 2011; 3 (93):93ra69. doi: 10.1126/scitranslmed.3002135 PMID: 21795589.
85. Jarmer J, Zlatkovic J, Tsouchnikas G, Vratskikh O, Strauss J, Aberle JH, et al. Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination. Journal of virology. 2014; 88(23):13845-57. doi: 10.1128/JVI.02086-14 PMID: 25253341.
86. Petrovsky N, Larena M, Siddharthan V, Prow NA, Hall RA, Lobigs M, et al. An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody. Journal of virology. 2013; 87(18):10324-33. doi: 10.1128/JVI.00480-13 PMID: 23864620; Pub Med Central PMCID: PMC3754008.
87. Takasaki T, Yabe S, Nerome R, Ito M, Yamada K, Kurane I. Partial protective effect of inactivated Japanese encephalitis vaccine on lethal West Nile virus infection in mice. Vaccine. 2003; 21(31):4514-8. PMID: 14575761.
88. Coler RN, Baldwin SL, Shaverdian N, Bertholet S, Reed SJ, Raman VS, et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PloS one. 2010; 5(10):e13677. doi: 10.1371/journal.pone.0013677 PMID: 21060869; Pub Med Central PMCID: PMC2965144.
89. Venter M, Swanepoel R. West Nile virus lineage 2 as a cause of zoonotic neurological disease in humans and horses in southern Africa. Vector borne and zoonotic diseases. 2010; 10(7):659-64. doi: 10.1089/vbz.2009.0230 PMID: 20854018.
90. Bakonyi T, Ferenczi E, Erdelyi K, Kutasi O, Csorgo T, Seidel B, et al. Explosive spread of a neuroinvasive lineage 2 West Nile virus in Central Europe, 2008/2009. Veterinary microbiology. 2013; 165(1-2):61-70. doi: 10.1016/j.vetmic.2013.03.005 PMID: 23570864.
91. Bakonyi T, Ivanics E, Erdelyi K, Ursu K, Ferenczi E, Weissenbock H, et al. Lineage 1 and 2 strains of encephalitic West Nile virus, central Europe. Emerging infectious diseases. 2006; 12(4):618-23. doi: 10.3201/eid1204.051379 PMID: 16704810; Pub Med Central PMCID: PMC3294705.